These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 31216226)

  • 1. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
    Tewari KS; Burger RA; Enserro D; Norquist BM; Swisher EM; Brady MF; Bookman MA; Fleming GF; Huang H; Homesley HD; Fowler JM; Greer BE; Boente M; Liang SX; Ye C; Bais C; Randall LM; Chan JK; Ferriss JS; Coleman RL; Aghajanian C; Herzog TJ; DiSaia PJ; Copeland LJ; Mannel RS; Birrer MJ; Monk BJ
    J Clin Oncol; 2019 Sep; 37(26):2317-2328. PubMed ID: 31216226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial.
    Wu X; Liu J; An R; Yin R; Zhang Y; Zhou H; He A; Wang L; Zhang J; Liu Z; Duan W; Zhu J; Lou G; Chen G; Cheng Y; Xue F; Nick S; Wang H; Li D
    J Gynecol Oncol; 2024 Sep; 35(5):e99. PubMed ID: 38872480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.
    Norquist BM; Brady MF; Harrell MI; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Burger RA; Tewari KS; Backes F; Mannel RS; Glaser G; Bailey C; Rubin S; Soper J; Lankes HA; Ramirez NC; King MC; Birrer MJ; Swisher EM
    Clin Cancer Res; 2018 Feb; 24(4):777-783. PubMed ID: 29191972
    [No Abstract]   [Full Text] [Related]  

  • 5. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
    Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
    Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Walker JL; Brady MF; Wenzel L; Fleming GF; Huang HQ; DiSilvestro PA; Fujiwara K; Alberts DS; Zheng W; Tewari KS; Cohn DE; Powell MA; Van Le L; Davidson SA; Gray HJ; Rose PG; Aghajanian C; Myers T; Alvarez Secord A; Rubin SC; Mannel RS
    J Clin Oncol; 2019 Jun; 37(16):1380-1390. PubMed ID: 31002578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
    Moore KN; Bookman M; Sehouli J; Miller A; Anderson C; Scambia G; Myers T; Taskiran C; Robison K; Mäenpää J; Willmott L; Colombo N; Thomes-Pepin J; Liontos M; Gold MA; Garcia Y; Sharma SK; Darus CJ; Aghajanian C; Okamoto A; Wu X; Safin R; Wu F; Molinero L; Maiya V; Khor VK; Lin YG; Pignata S
    J Clin Oncol; 2021 Jun; 39(17):1842-1855. PubMed ID: 33891472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
    Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
    N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
    Zhang L; Zhou Q
    Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
    Krasner CN; Castro C; Penson RT; Roche M; Matulonis UA; Morgan MA; Drescher C; Armstrong DK; Wolfe JK; Lee H; Supko JG; Seiden M; Birrer MJ; Dizon DS
    Gynecol Oncol; 2019 May; 153(2):223-229. PubMed ID: 30765148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group.
    Lai CH; Vallikad E; Lin H; Yang LY; Jung SM; Liu HE; Ou YC; Chou HH; Lin CT; Huang HJ; Huang KG; Qiu J; Hung YC; Wu TI; Chang WY; Tan KT; Lin CY; Chao A; Chang CJ
    J Gynecol Oncol; 2020 Jan; 31(1):e5. PubMed ID: 31788995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    Gillen J; Miller A; Bell-McGuinn KM; Schilder RJ; Walker JL; Mathews CA; Duska LR; Guntupalli SR; O'Cearbhaill R; Hays J; Hagemann AR; Gray HJ; Gordon SW; Armstrong DK; Chen A; Fracasso PM; Aghajanian C; Moore KN
    Gynecol Oncol; 2021 May; 161(2):512-515. PubMed ID: 33610319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
    Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
    Oza AM; Selle F; Davidenko I; Korach J; Mendiola C; Pautier P; Chmielowska E; Bamias A; DeCensi A; Zvirbule Z; González-Martín A; Hegg R; Joly F; Zamagni C; Gadducci A; Martin N; Robb S; Colombo N
    Int J Gynecol Cancer; 2017 Jan; 27(1):50-58. PubMed ID: 27749456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
    Gore M; Hackshaw A; Brady WE; Penson RT; Zaino R; McCluggage WG; Ganesan R; Wilkinson N; Perren T; Montes A; Summers J; Lord R; Dark G; Rustin G; Mackean M; Reed N; Kehoe S; Frumovitz M; Christensen H; Feeney A; Ledermann J; Gershenson DM
    Gynecol Oncol; 2019 Jun; 153(3):541-548. PubMed ID: 31005287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
    Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
    Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
    Provencher DM; Gallagher CJ; Parulekar WR; Ledermann JA; Armstrong DK; Brundage M; Gourley C; Romero I; Gonzalez-Martin A; Feeney M; Bessette P; Hall M; Weberpals JI; Hall G; Lau SK; Gauthier P; Fung-Kee-Fung M; Eisenhauer EA; Winch C; Tu D; MacKay HJ
    Ann Oncol; 2018 Feb; 29(2):431-438. PubMed ID: 29186319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
    Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
    JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.